Federal contract award
HHSO100201600038C
IGF::OT::IGF HOFFMANN-LAROCHE INC.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541711 |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $183.8M |
| Current contract value | $183.8M |
| Potential contract value / ceiling | $259.8M |
| Start date | Sep 15, 2016 |
| Current end date | Dec 31, 2028 |
| Potential end date | Dec 31, 2028 |
| Latest award activity | Aug 10, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 18 of 18 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 10, 2026 | P00017 | $8.1M | THE PURPOSE OF THIS MODIFICATION IS ADD SUPPLEMENTAL FUNDING FOR 0002 AND TO UPDATED THE PERIOD OF PERFORMANCE (POP) FOR CLIN 0001 TO END ON 12/31/2028. |
| Sep 25, 2025 | P00016 | $13.8M | THE PURPOSE OF THIS MODIFICATION IS ADD SUPPLEMENTAL FUNDING FOR CLIN 0001 & 0002 AND TO UPDATED THE PERIOD OF PERFORMANCE (POP) FOR CLIN 0001 TO END ON 12/31/2026. |
| Jun 24, 2025 | P00015 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE COST SHARE AMOUNT, EXTEND POP, UPDATE SOW, AND ADD SUPPLEMENTAL FUNDING TO CLIN 0002. |
| May 1, 2025 | P00014 | $4.7M | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE COST SHARE AMOUNT, EXTEND POP, UPDATE SOW, AND ADD SUPPLEMENTAL FUNDING TO CLIN 0002. |
| Feb 14, 2025 | P00013 | $29.1M | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE COST SHARE AMOUNT AND ADD SUPPLEMENTAL FUNDING TO CLIN 0002. |
| Jul 29, 2024 | P00012 | $3.0M | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE COST SHARE AMOUNT AND ADD SUPPLEMENTAL FUNDING TO CLIN 0002. |
| May 24, 2024 | P00011 | $9.3M | THE PURPOSE OF THIS MODIFICATION IS A NO COST EXTENSION, DE-OBLIGATE CANCELLING FUNDS, UPDATE COST SHARE AMOUNT, AND ADD SUPPLEMENTAL FUNDING TO CLIN 0002. |
| Jul 26, 2023 | P00010 | $2.0M | THE PURPOSE OF THIS MODIFICATION IS THE ADDITION OF SUPPLEMENTAL FUNDING OF $2,000,000 TO SUPPORT SOURCE DATA VERIFICATION, FULL ELECTRONIC MEDICAL RECORD UPLOADS, AND THE ADJUDICATION PROCESS FOR THE ONGOING REFERENCE RANGE AND CLINICAL PERFORMANCE |
| Apr 13, 2023 | P00009 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO DE-OBLIGATE EXCESS AND CANCELLING FUNDS |
| Sep 27, 2022 | P00008 | $-2.4M | THE PURPOSE OF THIS MODIFICATION IS TO DE-OBLIGATE EXCESS AND CANCELLING FUNDS |
| Aug 31, 2022 | P00007 | $0 | THE PURPOSE OF THIS MODIFICATION/AMENDMENT IS TO DO THE FOLLOWING CLIN 0002 MODIFICATIONS: THE ADDITION OF THE FG-LPXC LUNG PROGRAM TO CLIN 0002. THE PROGRAM IS WITHIN THE SCOPE OF CLIN 0002 DEVELOPING ADDITIONAL PRECLINICAL CANDIDATES FOR ENTRY- |
| Jun 1, 2022 | P00006 | $3.2M | THE PURPOSE OF THIS MODIFICATION IS TO: (1) UPDATE THE OTHER TRANSACTION AGREEMENTS OFFICER (OTAO); (2) DELETE ATTACHMENT 1, STATEMENT OF WORK, DATED SEPTEMBER 24, 2018 IN ITS ENTIRETY AND REPLACE IT WITH ATTACHMENT 1, STATEMENT OF WORK, DATED OCTOBE |
| Oct 29, 2020 | P00005 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: (1) UPDATE THE OTHER TRANSACTION AGREEMENTS OFFICER (OTAO); (2) DELETE ATTACHMENT 1, STATEMENT OF WORK, DATED SEPTEMBER 24, 2018 IN ITS ENTIRETY AND REPLACE IT WITH ATTACHMENT 1, STATEMENT OF WORK, DATED OCTOBE |
| Feb 21, 2020 | P00004 | $0 | THE PURPOSE OF MODIFICATION 0004 IS TO (1) REVISE THE PERIOD OF PERFORMANCE; (2) REVISE THE RECIPIENT COST SHARE BUDGET AND (3) REVISE ATTACHMENT 4 (ROCHE BARDA AFFILIATE LIST |
| Jul 26, 2019 | P00003 | $0 | THE PURPOSE OF MODIFICATION 0003 IS TO (1) REVISE THE PERIOD OF PERFORMANCE; (2) REVISE THE POCS AND (3) CHANGE THE POC FOR PAYMENTS. |
| Feb 22, 2019 | 2 | $0 | MODIFICATION 0002 |
| Sep 26, 2018 | 1 | $78.0M | PURPOSE: THE MODIFICATION 0001 SERVES SEVEN PURPOSES: (1) IN ARTICLE II(A) TERM OF THIS AGREEMENT: EXTEND THE CLIN 0001 PERIOD OF PERFORMANCE AT NO ADDITIONAL COST FROM: SEPTEMBER 15, 2016 THROUGH DECEMBER 14, 2018 TO: SEPTEMBER 26, 2018 THROUGH JULY 31, 2019. (2) EXERCISE CLIN 0002 FOR A TOTAL COST SHARE OF $119,701,251 ; THE PERIOD OF PERFORMANCE (PPM) FOR CLIN 0002 IS 60 MONTHS OR 5 YEARS. (3) IN ARTICLE IV (A) MANAGEMENT OF PROJECT: UPDATE JOC MEMBERS: (BARDA) JOSEPH LARSEN IS REPLACED WITH MARK ALBRECHT; (ROCHE) STEPHAN M. LAAGE-WITT IS REPLACED WITH MARK EISNER, DAVID M LEE IS REPLACED WITH JOHN YOUNG, AND OLIVER LIESENFELD IS REPLACED WITH PAUL BAU; (4) IN ARTICLE V(A) AGREEMENT ADMINISTRATION: UPDATE POC(S): (BARDA) ANDREW ALBRIGHT AND CHRIS HOUCHENS ARE REPLACED WITH BRIAN TSE AND OXANA SELIVANOVA; (ROCHE) STEPHAN LAAGE-WITT IS REPLACED WITH VOLKER STUCKE FOR ADMINISTRATIVE AND CONTRACTUAL MATTERS, KEN BRADLEY FOR ADVANCED DEVELOPMENT TECHNICAL MATTERS AND PAUL BAUM FOR DIAGNOSTICS PLATFORM TECHNICAL MATTERS. (5) IN ARTICLE VI(C) COST SHARING: REVISE THE TOTAL PROJECT COST SUMMARY TO INCLUDE EXECUTED OPTION 1 (CLIN 0002) SHARED COST TOTALING $113,129,841; (6) IN ATTACHMENT 1: DELETE THE STATEMENT OF WORK (SOW) DATED AUGUST 30, 2016 IN ITS ENTIRETY AND REPLACE WITH SOW DATED SEPTEMBER 24, 2018; (7) IN ATTACHMENT 3: DELETE PORTFOLIO PERFORMANCE METRICS (PPM) DATED SEPTEMBER 15, 2016 AND REPLACE WITH PPM DATED SEPTEMBER 24, 2018. |
| Sep 15, 2016 | 0 | $35.2M | IGF::OT::IGF HOFFMANN-LAROCHE INC. |
Estimated positioning window
Dec 31, 2027 – Jun 30, 2028
Recompete signal: . Rule-based research score; positioning dates are estimates.
60/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 60/100. Available recorded signals: 55 points.
- Contract end 2028-12-31 (798 days from calculation)
- +15 points
- 40 historical awards in this buyer and category group
- +15 points
- 18 recorded award transactions
- +10 points
- Latest award action: 2026-08-10
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.